丙酸氟替卡松联合孟鲁司特治疗小儿哮喘的疗效探讨

李影明

[摘要] 目的 分析丙酸氟替卡松聯合孟鲁司特治疗小儿哮喘的疗效。 方法 选择2019年1月～2020年1月我院收治的110例小儿哮喘患儿作为研究对象，按照随机数表法分为两组。对照组55例，在常规治疗的基础上给予丙酸氟替卡松气雾剂吸入治疗;实验组55例，在对照组的基础上联合使用孟鲁司特钠咀嚼片治疗。治疗6个月后，比较两组患儿的临床疗效、不良反应及治疗前后的临床症状积分、肺功能指标、炎症指标、气道重塑指标变化情况。 结果 实验组总有效率为92.73%（51/55），显著高于对照组的78.18%（43/55）（P<0.05）;治疗前两组患儿FEV1、PEF、FEV1/FVC、LA、WA、TA、hs-CRP、TNF-α、IL-8、日间症状、夜间症状评分比较，差异无统计学意义（P>0.05）;治疗后两组FEV1、PEF、FEV1/FVC、LA、TA均显著提高（P<0.05），且实验组各指标值均显著高于对照组（P<0.05）;治疗后两组WA、hs-CRP、TNF-α、IL-8、日间症状、夜间症状评分均显著降低（P<0.05），且实验组各指标值均显著低于对照组（P<0.05）;两组患儿治疗期间不良反应发生情况比较，差异无统计学意义（P>0.05）。结论 采用丙酸氟替卡松联合孟鲁司特治疗小儿哮喘，能够提高临床疗效，有效抑制炎症反应，增强肺功能，逆转气道重塑进程，改善症状，且安全性良好。

[关键词] 丙酸氟替卡松;孟鲁司特;小儿哮喘;临床疗效

[中图分类号] R725.6          [文献标识码] B          [文章编号] 1673-9701（2020）28-0084-04

Efficacy investigation of fluticasone propionate combined with montelukast in the treatment of infantile asthma

LI Yingming

Department of Pediatrics， Maternal and Child Health Care Hospital in Jiamusi City in Heilongjiang Province， Jiamusi   154002， China

[Abstract] Objective To analyze the efficacy of fluticasone propionate combined with montelukast in the treatment of infantile asthma. Methods From January 2019 to January 2020， a total of 110 children with asthma admitted to our hospital were selected as the research objects， and they were divided into two groups according to the random number table method. The control group（n=55） was treated with fluticasone propionate aerosol inhalation on the basis of routine treatment， and the observation group（n=55） was treated with montelukast sodium chewable tablets on the basis of the control group. After 6 months of treatment， the changes of clinical efficacy， adverse reactions（ADRs）， clinical symptom scores before and after treatment， pulmonary function index， inflammatory index， airway remodeling index were compared between the two groups. Results The total efficacy rate of the experimental group was 92.73%（51/55）， which was significantly higher than 78.18%（43/55） of the control group（P<0.05）. Before treatment， there were no significant differences in FEV1， PEF， FEV1/FVC， LA， WA， TA， hs-CRP， TNF-α， IL-8， daytime symptoms and nighttime symptoms scores between the two groups（P>0.05）. After treatment， FEV1， PEF， FEV1/FVC， LA， TA in both groups were significantly increased（P<0.05）， and all indexes in the experimental group were significantly higher than those in the control group（P<0.05）. The scores of WA， hs-CRP， TNF-α， IL-8， daytime symptoms and nighttime symptoms in both groups were all decreased significantly after treatment（P<0.05）， and the experimental group was significantly lower than the control group（P<0.05）. There were no significant differences in ADRs between the two groups during the treatment（P>0.05）. Conclusion The combination of fluticasone propionate and montelukast in the treatment of infantile asthma improve the clinical efficacy， effectively inhibit inflammatory reaction， enhance pulmonary function， reverse airway remodeling process， improve symptoms， and have good safety.